<DOC>
	<DOC>NCT00796159</DOC>
	<brief_summary>This is a Post-Marketing Surveillance study evaluating the Efficacy, Tolerability and Safety of Olmesartan medoxomil 20 mg in combination with 12.5 MG of hydrochlorothiazide in subjects with mild to moderate essential hypertension</brief_summary>
	<brief_title>Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide</brief_title>
	<detailed_description>Non Probability Sampling</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male and Female patients 18 to 65 y/old Patient previously taking lowdose medoxomil or any other ARB alone with uncontrolled BP Patient with uncontrolled mild to moderate hypertension (SBP&gt;= 140 and &lt;=179 mmHg OR DBP of &gt;=90 and &lt;=109 mmHg) Pregnant of Lactating women History of secondary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Efficacy; Tolerability; Safety; Essential Hypertension</keyword>
</DOC>